Fan Xiaoqi sorted
(Washington Reuters)According to the laboratory test, Modner Crown Vaccine Adding Agent can effectively combat the rapidly spreading Omikon mutant strain; compared with only two doses of vaccine, the additional additional additional agent can greatly improve the level of antibody.
Modner said that this means that its existing crown vaccine can continue to become "the first line of defense against Omikon", that is, the company will still focus on the current MRNA-1273 On the Modner vaccine, to deal with Omikon, which is highly transmitted.
However, Modner still plans to develop a vaccine specifically for Omikon, and hopes to start clinical trials early next year.
Modner Chief Medical Officer Burton pointed out in an interview that the existing Modner vaccine is very effective and safe.He said that the end of the end of the year and the coming of winter will survive the case of Omikon, but he believes that the Modner vaccine can provide sufficient protection for people.
According to Modner, the two -dose Modner vaccine can cause the human body to produce a low neutral and neutral antibody against Omikon, but the additional additional additional additional additional additions can increase the antibody by 37 times; if it is 100 micrograms, it is 100 microgramsAdding agents can increase the level of antibody to 80 times.
In the relevant experiments of Modner, the researchers tested the artificially cultivated Omircor pseudo virus with the blood of the Modner vaccine, and obtained the above data.Although the relevant data has not yet been reviewed by the peers, it is similar to the data recently mentioned by the US government's chief infectious disease expert.
Modner also shows that although there is a little possibility of 100 micrograms of additional additions, it is generally safe and good tolerance.
In this regard, Burton pointed out whether the additional additional additional pursuit of this dose will be measured and decided by the government and regulatory agencies.
The Modner approved by the U.S. regulatory authorities in October was 50 micrograms, which was half of the first and second doses of vaccine; the dose of the first two doses of the first two doses was 100 micrograms per dose.
